18 Mar 2013, BioSpectrum Bureau , BioSpectrum
Singapore: Dainippon Sumitomo Pharma (DSP), headquartered in Japan, and Nippon Shinyaku, also a Japanese company, have concluded a license agreement for exclusive rights to develop, manufacture and commercialize SMP-986 in Japan, a new therapeutic agent for overactive bladder created by DSP.
Completing phase II studies in Japan, Europe and the US, DSP was searching for a partner with a strong presence in urology. As a result, DSP chose Nippon Shinyaku as its best partner for the Japanese market. Under this agreement, Nippon Shinyaku obtains exclusive rights to develop, manufacture and commercialize SMP-986 in Japan for general urological diseases. In return, Nippon Shinyaku will pay DSP an upfront fee and make development milestone payments. In addition, after launch Nippon Shinyaku will also pay DSP royalties according to sales amounts and milestone payments in accordance with sales goals.
SMP-986 possesses the dual pharmacological actions of muscarinic receptor antagonism and inhibition through Na+-channel blockade. In the future, Nippon Shinyaku plans to proceed with the development of SMP-986 to obtain approval for the indication of nocturia. Nippon Shinyaku hopes that by promoting the development of SMP-986 and providing it to the medical field as soon as possible it can better the lives of patients.
DSP hopes that the future approval and launch of SMP-986 will contribute to healthcare and medical treatment for urology in Japan.